BMRN Stock Analysis: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$58.99
1.17 (2.02%)
▲
5d:
+2.86%
30d:
+10.63%
90d:
+3.06%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 03, 2026
30d
Smart Money Accumulation
None View Scanner →
Strength: 5.1/10
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 1.0% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 1.0% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$118.32
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$73.47
19.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $58.99, which is considered extended relative to its 30-day fair value range of $54.24 to $57.75. The stock's valuation (Forward PE: 9.1) is in line with its historical norms (9.4). Remarkably, the market is currently pricing in an annual earnings decline of 1.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BMRN is in a downtrend. The price is approaching resistance at $59.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $87.85 (+48.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMRN is in a downtrend. The price is approaching resistance at $59.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $87.85 (+48.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$54.24 -
$57.75
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.9% below Wall St target ($87.85)
Trading Range Analysis
30-Day Trading Range
$54.24 -
$57.75
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$54.26
Resistance Level
$59.77
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.13
Wall Street Target
$87.85
(+48.9%)
Revenue Growth (YoY)
2.8%
Earnings Growth (YoY)
-43.1%
Profit Margin
8.3%
Valuation Discount vs History
-1.0% cheaper
PE vs Historical
9.1 vs 9.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.0%
(market-implied from PE analysis)
1-Year Target
$58.40
(-1%)
2-Year Target
$57.82
(-2%)
3-Year Target
$57.24
(-3%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
$58.95
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 30.9%)
$315.91
(+436%)
Base:
(SPY PE: 9.1, Growth: 30.9%)
$132.38
(+124%)
Bear:
(PE: 7.8, Growth: 30.9%)
$112.52
(+91%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (42x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 41.60 | Current EPS (TTM): $1.39
Bull Case
$127.20
(+116%)
Analyst growth 100.0%, PE expands to 45.8
Base Case
$115.64
(+96%)
Market implied 100.0%, PE stable at 41.6
Bear Case
$39.32
(-33%)
Severe decline -20.0%, PE contracts to 35.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.1 to 9.4
Stabilization Target:
$60.76
(+3.0%)
PE Expansion Potential:
+3.0%
Share & Embed Analysis
Last updated: July 03, 2026 6:23 PM ET
Data refreshes hourly during market hours. Next update: 7:23 PM
Data refreshes hourly during market hours. Next update: 7:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles Greg Guyer
SELL
16486 shares
2026-03-11
Gregory R Friberg
SELL
6326 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
